Skip to search formSkip to main contentSkip to account menu

clivatuzumab

Known as: PAM4 antibody, clivatuzumab tetraxetan, hPAM4 antibody 
A humanized monoclonal antibody directed against the pancreatic cancer antigen MUC1, with potential antineoplastic activity. Clivatuzumab binds to… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Monoclonal Antibodies
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Optical-Based Underwater Communications
A high-speed 24 Gb/s PAM4 optical-based underwater communication (OBUC) with afocal scheme for reducing/expanding collimated beam… 
2018
2018
Retour d’expérience d’une inspection ANSM sur un essai clinique d’un médicament radiopharmaceutique innovant
2017
2017
DSP equalization-free data center communication with high dispersion tolerant optical duobinary-PAM4 signal
We propose and experimentally evaluate the dispersion tolerance of a data center communication system with DSP equalization free… 
2017
2017
Transceivers for inter-data center connections
We discuss options for data-center interconnects with reaches up to 80 km. Besides coherent transmission, direct detect solutions… 
2015
2015
A 50Gb/s low power PAM4 SerDes transmitter with 4-tap FFE and high linearity output voltage in 65nm CMOS technology
This paper presents a 50Gb/s low power PAM4 transmitter with 4-tap FFE and high linearity output voltage. By employing a low… 
2012
2012
Activity of fractionated radioimmunotherapy (RAIT) with 90Y clivatuzumab tetraxetan (90Y-hPAM4) plus gemcitabine (Gem) in advanced pancreatic cancer (APC): Final results from a two-part study.
227 Background: A Phase I/II trial was undertaken to evaluate repeated cycles of 90Y-labeled anti-mucin humanized mAb (90Y-hPAM4… 
2011
2011
Activity of fractionated radioimmunotherapy with clivatuzumab tetraxetan combined with low-dose gemcitabine (Gem) in advanced pancreatic cancer (APC).
240 Background: The90Y-labeled anti-mucin humanized mAb, clivatuzumab tetraxetan (90Y-hPAM4), is in clinical development in APC… 
2010
2010
Therapeutic effects of fractionated radioimmunotherapy (RAIT) with clivatuzumab tetraxetan combined with low-dose gemcitabine (Gem) in advanced pancreatic cancer (APC).
4115 Background: Since a single dose of 90Y-labeled anti-mucin humanized mAb, clivatuzumab tetraxetan (90Y-hPAM4), showed… 
2009
2009
Multicenter study of radiosensitizing gemcitabine combined with fractionated radioimmunotherapy for repeated treatment cycles in advanced pancreatic cancer.
4620 Background: In a phase I study, a single dose of 90Y-labeled anti-mucin humanized antibody, hPAM4 (90Y-hPAM4), led to… 
Highly Cited
2001
Highly Cited
2001
Therapeutic advantage of (90)yttrium- versus (131)iodine-labeled PAM4 antibody in experimental pancreatic cancer.
OBJECTIVES Radioimmunotherapy studies using (131)I-PAM4 have demonstrated significant antitumor effects in mice bearing human… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)